Adverse reactions of Quizartinib and countermeasures

Quizartinib (Quizartinib), trade name Vanflyta, is an oral tyrosine kinase inhibitor mainly used to treat patients with FLT3-ITD mutations in acute myeloid leukemia (AML). FLT3-ITD mutations are common in AML patients and are closely associated with poor prognosis, high relapse rate, and short survival. Quizartinib successfully blocks the proliferation signals of leukemia cells by targeting the activity of FLT3 kinase, thereby providing an effective treatment option for these patients.

Although quizartinib shows positive efficacy in treatment, a series of adverse reactions may occur during the medication, and patients and medical teams need to pay great attention to this. Among them, the most common side effect is a decrease in white blood cell count, accompanied by possible fever. This condition may cause the patient's immune system to be suppressed, thereby increasing the risk of infection. In addition, reduced levels of electrolytes such as potassium, magnesium or calcium in the blood may also have an impact on heart function and other physiological processes, so regular monitoring and timely correction are required.

Elevated levels of liver or muscle enzymes may indicate liver or muscle damage, so regular checkups are necessary and treatment may be adjusted if necessary. Gastrointestinal symptoms are also a common problem during treatment with Quizartinib, and patients may experience diarrhea, nausea, vomiting, and abdominal pain. These symptoms can usually be alleviated by adjusting diet, using medications, and implementing symptomatic treatments. Oral ulcers or mucositis may also occur, affecting the patient's ability to eat and feel comfortable. At this time, appropriate oral care and topical medication are required.

Sepsis is a serious comorbidity that may occur in patients receiving quizartinib and requires immediate medical attention and anti-infective treatment. Mild symptoms such as headaches and upper respiratory tract infections usually improve with rest and related symptomatic treatment.

In order to effectively manage these adverse reactions, patients should use quizartinib rationally under the guidance of a doctor and receive regular physical examination and monitoring. Once any uncomfortable symptoms occur, you should communicate with your doctor in time so that the treatment plan can be adjusted as soon as possible to ensure the safety and effectiveness of the treatment. At the same time, cultivating good living habits and maintaining a positive attitude are also important means to reduce adverse reactions and improve quality of life. In short, fully understanding and properly dealing with potential adverse reactions of quizartinib will help patients achieve better results during treatment.

xa0

Reference materials:https://www.drugs.com/mtm/quizartinib.html